ArticlePloS one2025
An autoencoder learning method for predicting breast cancer subtypes.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Heterogeneity of breast cancer poses several challenges for detection and treatment. With next-generation sequencing, we can now map the transcriptional profile of each patient's breast tissue, which has the potential for identifying and characterizing cancer subtypes. However, the large dimensionality of this transcriptomic data and the heterogeneity between the molecular profiles of breast cancers poses a barrier to identifying minimal markers and mechanistic consequences. In this study, we develop an autoencoder to identify a reduced set of gene markers that characterize the four major breast cancer subtypes with the accuracy of 82.38%. The reduced feature space created by our model captures the functional characteristics of each breast cancer subtype highlighting mechanisms that are unique to each subtype as well as those that are shared. Our high prediction accuracy shows that our markers can be valuable for breast cancer subtype detection and have the potential to provide insights into mechanisms associated with each subtype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.